Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 230

1.

Efficacy of Delayed Therapy with Fosmanogepix (APX001) in a Murine Model of Candida auris Invasive Candidiasis.

Wiederhold NP, Najvar LK, Shaw KJ, Jaramillo R, Patterson H, Olivo M, Catano G, Patterson TF.

Antimicrob Agents Chemother. 2019 Aug 19. pii: AAC.01120-19. doi: 10.1128/AAC.01120-19. [Epub ahead of print]

2.

Extended-Interval Dosing of Rezafungin against Azole-Resistant Aspergillus fumigatus.

Wiederhold NP, Najvar LK, Jaramillo R, Olivo M, Wickes BL, Catano G, Patterson TF.

Antimicrob Agents Chemother. 2019 Aug 12. pii: AAC.01165-19. doi: 10.1128/AAC.01165-19. [Epub ahead of print]

3.

Utility of CT assessment in hematology patients with invasive aspergillosis: a post-hoc analysis of phase 3 data.

Jin J, Wu D, Liu Y, Pan S, Yan JL, Aram JA, Lou YJ, Meng H, Chen X, Zhang X, Schwartz IS, Patterson TF.

BMC Infect Dis. 2019 May 28;19(1):471. doi: 10.1186/s12879-019-4039-7.

4.

Current Concepts and Future Directions in the Pharmacology and Treatment of Coccidioidomycosis.

Thompson GR 3rd, Lewis JS 2nd, Nix DE, Patterson TF.

Med Mycol. 2019 Feb 1;57(Supplement_1):S76-S84. doi: 10.1093/mmy/myy029. Review.

PMID:
30690601
5.

New Concepts in Diagnostics for Invasive Mycoses: Non-Culture-Based Methodologies.

Patterson TF, Donnelly JP.

J Fungi (Basel). 2019 Jan 17;5(1). pii: E9. doi: 10.3390/jof5010009. Review.

6.

The Fungal Cyp51-Specific Inhibitor VT-1598 Demonstrates In Vitro and In Vivo Activity against Candida auris.

Wiederhold NP, Lockhart SR, Najvar LK, Berkow EL, Jaramillo R, Olivo M, Garvey EP, Yates CM, Schotzinger RJ, Catano G, Patterson TF.

Antimicrob Agents Chemother. 2019 Feb 26;63(3). pii: e02233-18. doi: 10.1128/AAC.02233-18. Print 2019 Mar.

7.

In Vivo Efficacy of VT-1129 against Experimental Cryptococcal Meningitis with the Use of a Loading Dose-Maintenance Dose Administration Strategy.

Wiederhold NP, Xu X, Wang A, Najvar LK, Garvey EP, Ottinger EA, Alimardanov A, Cradock J, Behnke M, Hoekstra WJ, Brand SR, Schotzinger RJ, Jaramillo R, Olivo M, Kirkpatrick WR, Patterson TF.

Antimicrob Agents Chemother. 2018 Oct 24;62(11). pii: e01315-18. doi: 10.1128/AAC.01315-18. Print 2018 Nov.

8.

Screening a Repurposing Library for Inhibitors of Multidrug-Resistant Candida auris Identifies Ebselen as a Repositionable Candidate for Antifungal Drug Development.

Wall G, Chaturvedi AK, Wormley FL Jr, Wiederhold NP, Patterson HP, Patterson TF, Lopez-Ribot JL.

Antimicrob Agents Chemother. 2018 Sep 24;62(10). pii: e01084-18. doi: 10.1128/AAC.01084-18. Print 2018 Oct.

9.

The Fungal Cyp51 Inhibitor VT-1129 Is Efficacious in an Experimental Model of Cryptococcal Meningitis.

Wiederhold NP, Najvar LK, Garvey EP, Brand SR, Xu X, Ottinger EA, Alimardanov A, Cradock J, Behnke M, Hoekstra WJ, Schotzinger RJ, Jaramillo R, Olivo M, Kirkpatrick WR, Patterson TF.

Antimicrob Agents Chemother. 2018 Aug 27;62(9). pii: e01071-18. doi: 10.1128/AAC.01071-18. Print 2018 Sep.

10.

The Orotomide Olorofim Is Efficacious in an Experimental Model of Central Nervous System Coccidioidomycosis.

Wiederhold NP, Najvar LK, Jaramillo R, Olivo M, Birch M, Law D, Rex JH, Catano G, Patterson TF.

Antimicrob Agents Chemother. 2018 Aug 27;62(9). pii: e00999-18. doi: 10.1128/AAC.00999-18. Print 2018 Sep.

11.

Blastomyces helicus, a New Dimorphic Fungus Causing Fatal Pulmonary and Systemic Disease in Humans and Animals in Western Canada and the United States.

Schwartz IS, Wiederhold NP, Hanson KE, Patterson TF, Sigler L.

Clin Infect Dis. 2019 Jan 7;68(2):188-195. doi: 10.1093/cid/ciy483.

12.

Emergomyces canadensis, a Dimorphic Fungus Causing Fatal Systemic Human Disease in North America.

Schwartz IS, Sanche S, Wiederhold NP, Patterson TF, Sigler L.

Emerg Infect Dis. 2018 Apr;24(4):758-761. doi: 10.3201/eid2404.171765.

13.

The Novel Fungal Cyp51 Inhibitor VT-1598 Is Efficacious in Experimental Models of Central Nervous System Coccidioidomycosis Caused by Coccidioides posadasii and Coccidioides immitis.

Wiederhold NP, Shubitz LF, Najvar LK, Jaramillo R, Olivo M, Catano G, Trinh HT, Yates CM, Schotzinger RJ, Garvey EP, Patterson TF.

Antimicrob Agents Chemother. 2018 Mar 27;62(4). pii: e02258-17. doi: 10.1128/AAC.02258-17. Print 2018 Apr.

14.

The Emerging Threat of Antifungal Resistance in Transplant Infectious Diseases.

Schwartz IS, Patterson TF.

Curr Infect Dis Rep. 2018 Feb 5;20(3):2. doi: 10.1007/s11908-018-0608-y. Review.

PMID:
29404711
15.

Novel approaches to antifungal therapy.

Thompson GR 3rd, Patterson TF.

Am J Transplant. 2018 Feb;18(2):287-288. doi: 10.1111/ajt.14616. Epub 2018 Jan 8. No abstract available.

16.

Impact of unresolved neutropenia in patients with neutropenia and invasive aspergillosis: a post hoc analysis of the SECURE trial.

Kontoyiannis DP, Selleslag D, Mullane K, Cornely OA, Hope W, Lortholary O, Croos-Dabrera R, Lademacher C, Engelhardt M, Patterson TF.

J Antimicrob Chemother. 2018 Mar 1;73(3):757-763. doi: 10.1093/jac/dkx423.

PMID:
29194488
17.

Oral glucan synthase inhibitor SCY-078 is effective in an experimental murine model of invasive candidiasis caused by WT and echinocandin-resistant Candida glabrata.

Wiederhold NP, Najvar LK, Jaramillo R, Olivo M, Pizzini J, Catano G, Patterson TF.

J Antimicrob Chemother. 2018 Feb 1;73(2):448-451. doi: 10.1093/jac/dkx422.

18.

Multidrug-Resistant Candida: Epidemiology, Molecular Mechanisms, and Treatment.

Arendrup MC, Patterson TF.

J Infect Dis. 2017 Aug 15;216(suppl_3):S445-S451. doi: 10.1093/infdis/jix131. Review.

PMID:
28911043
19.

Multiple Brain Abscesses Caused by Trichosporon inkin in a Patient with X-Linked Chronic Granulomatous Disease (CGD) Successfully Treated with Antifungal Therapy.

Hajjar J, Restrepo A, Javeri H, Wiederhold NP, Papanastassiou AM, Patterson TF.

J Clin Immunol. 2017 Aug;37(6):519-523. doi: 10.1007/s10875-017-0419-1. Epub 2017 Jul 11. No abstract available.

PMID:
28698914
20.

Prophylactic Treatment with VT-1161 Protects Immunosuppressed Mice from Rhizopus arrhizus var. arrhizus Infection.

Gebremariam T, Alkhazraji S, Lin L, Wiederhold NP, Garvey EP, Hoekstra WJ, Schotzinger RJ, Patterson TF, Filler SG, Ibrahim AS.

Antimicrob Agents Chemother. 2017 Aug 24;61(9). pii: e00390-17. doi: 10.1128/AAC.00390-17. Print 2017 Sep.

21.

The Carbohydrate Lectin Receptor Dectin-1 Mediates the Immune Response to Exserohilum rostratum.

Reedy JL, Negoro PE, Feliu M, Lord AK, Khan NS, Lukason DP, Wiederhold NP, Tam JM, Mansour MK, Patterson TF, Vyas JM.

Infect Immun. 2017 Feb 23;85(3). pii: e00903-16. doi: 10.1128/IAI.00903-16. Print 2017 Mar.

22.

Modified release itraconazole amorphous solid dispersion to treat Aspergillus fumigatus: importance of the animal model selection.

Maincent JP, Najvar LK, Kirkpatrick WR, Huang S, Patterson TF, Wiederhold NP, Peters JI, Williams RO 3rd.

Drug Dev Ind Pharm. 2017 Feb;43(2):264-274. doi: 10.1080/03639045.2016.1236811. Epub 2016 Oct 5.

23.

The Celecoxib Derivative AR-12 Has Broad-Spectrum Antifungal Activity In Vitro and Improves the Activity of Fluconazole in a Murine Model of Cryptococcosis.

Koselny K, Green J, DiDone L, Halterman JP, Fothergill AW, Wiederhold NP, Patterson TF, Cushion MT, Rappelye C, Wellington M, Krysan DJ.

Antimicrob Agents Chemother. 2016 Nov 21;60(12):7115-7127. Print 2016 Dec.

24.

Effect of Antifungal Treatment in a Diet-Based Murine Model of Disseminated Candidiasis Acquired via the Gastrointestinal Tract.

Kadosh D, Najvar LK, Bocanegra R, Olivo M, Kirkpatrick WR, Wiederhold NP, Patterson TF.

Antimicrob Agents Chemother. 2016 Oct 21;60(11):6703-6708. doi: 10.1128/AAC.01144-16. Print 2016 Nov.

25.

Executive Summary: Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America.

Patterson TF, Thompson GR 3rd, Denning DW, Fishman JA, Hadley S, Herbrecht R, Kontoyiannis DP, Marr KA, Morrison VA, Nguyen MH, Segal BH, Steinbach WJ, Stevens DA, Walsh TJ, Wingard JR, Young JA, Bennett JE.

Clin Infect Dis. 2016 Aug 15;63(4):433-42. doi: 10.1093/cid/ciw444.

26.

Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America.

Patterson TF, Thompson GR 3rd, Denning DW, Fishman JA, Hadley S, Herbrecht R, Kontoyiannis DP, Marr KA, Morrison VA, Nguyen MH, Segal BH, Steinbach WJ, Stevens DA, Walsh TJ, Wingard JR, Young JA, Bennett JE.

Clin Infect Dis. 2016 Aug 15;63(4):e1-e60. doi: 10.1093/cid/ciw326. Epub 2016 Jun 29.

27.

Isavuconazole Is Effective for the Treatment of Experimental Cryptococcal Meningitis.

Wiederhold NP, Kovanda L, Najvar LK, Bocanegra R, Olivo M, Kirkpatrick WR, Patterson TF.

Antimicrob Agents Chemother. 2016 Aug 22;60(9):5600-3. doi: 10.1128/AAC.00229-16. Print 2016 Sep.

28.

Repurposing auranofin as an antifungal: In vitro activity against a variety of medically important fungi.

Wiederhold NP, Patterson TF, Srinivasan A, Chaturvedi AK, Fothergill AW, Wormley FL, Ramasubramanian AK, Lopez-Ribot JL.

Virulence. 2017 Feb 17;8(2):138-142. doi: 10.1080/21505594.2016.1196301. Epub 2016 Jun 7.

29.

Invasive Aspergillosis: Current Strategies for Diagnosis and Management.

Cadena J, Thompson GR 3rd, Patterson TF.

Infect Dis Clin North Am. 2016 Mar;30(1):125-42. doi: 10.1016/j.idc.2015.10.015. Review.

PMID:
26897064
30.

Comparison of Nonculture Blood-Based Tests for Diagnosing Invasive Aspergillosis in an Animal Model.

White PL, Wiederhold NP, Loeffler J, Najvar LK, Melchers W, Herrera M, Bretagne S, Wickes B, Kirkpatrick WR, Barnes RA, Donnelly JP, Patterson TF.

J Clin Microbiol. 2016 Apr;54(4):960-6. doi: 10.1128/JCM.03233-15. Epub 2016 Jan 20.

31.

The Investigational Fungal Cyp51 Inhibitor VT-1129 Demonstrates Potent In Vitro Activity against Cryptococcus neoformans and Cryptococcus gattii.

Lockhart SR, Fothergill AW, Iqbal N, Bolden CB, Grossman NT, Garvey EP, Brand SR, Hoekstra WJ, Schotzinger RJ, Ottinger E, Patterson TF, Wiederhold NP.

Antimicrob Agents Chemother. 2016 Mar 25;60(4):2528-31. doi: 10.1128/AAC.02770-15. Print 2016 Apr.

32.

Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial.

Maertens JA, Raad II, Marr KA, Patterson TF, Kontoyiannis DP, Cornely OA, Bow EJ, Rahav G, Neofytos D, Aoun M, Baddley JW, Giladi M, Heinz WJ, Herbrecht R, Hope W, Karthaus M, Lee DG, Lortholary O, Morrison VA, Oren I, Selleslag D, Shoham S, Thompson GR 3rd, Lee M, Maher RM, Schmitt-Hoffmann AH, Zeiher B, Ullmann AJ.

Lancet. 2016 Feb 20;387(10020):760-9. doi: 10.1016/S0140-6736(15)01159-9. Epub 2015 Dec 10.

PMID:
26684607
33.

The novel arylamidine T-2307 demonstrates in vitro and in vivo activity against echinocandin-resistant Candida glabrata.

Wiederhold NP, Najvar LK, Fothergill AW, Bocanegra R, Olivo M, McCarthy DI, Fukuda Y, Mitsuyama J, Patterson TF.

J Antimicrob Chemother. 2016 Mar;71(3):692-5. doi: 10.1093/jac/dkv398. Epub 2015 Nov 29.

34.

Emergence of Azole Resistance in Aspergillus.

Wiederhold NP, Patterson TF.

Semin Respir Crit Care Med. 2015 Oct;36(5):673-80. doi: 10.1055/s-0035-1562894. Epub 2015 Sep 23. Review.

PMID:
26398534
35.

What's new in antifungals: an update on the in-vitro activity and in-vivo efficacy of new and investigational antifungal agents.

Wiederhold NP, Patterson TF.

Curr Opin Infect Dis. 2015 Dec;28(6):539-45. doi: 10.1097/QCO.0000000000000203. Review.

PMID:
26374950
36.

VT-1161 Protects Immunosuppressed Mice from Rhizopus arrhizus var. arrhizus Infection.

Gebremariam T, Wiederhold NP, Fothergill AW, Garvey EP, Hoekstra WJ, Schotzinger RJ, Patterson TF, Filler SG, Ibrahim AS.

Antimicrob Agents Chemother. 2015 Dec;59(12):7815-7. doi: 10.1128/AAC.01437-15. Epub 2015 Sep 14.

37.

Aspergillus Polymerase Chain Reaction: Systematic Review of Evidence for Clinical Use in Comparison With Antigen Testing.

White PL, Wingard JR, Bretagne S, Löffler J, Patterson TF, Slavin MA, Barnes RA, Pappas PG, Donnelly JP.

Clin Infect Dis. 2015 Oct 15;61(8):1293-303. doi: 10.1093/cid/civ507. Epub 2015 Jun 25. Review.

38.

Phaeohyphomycosis in transplant recipients: Results from the Transplant Associated Infection Surveillance Network (TRANSNET).

McCarty TP, Baddley JW, Walsh TJ, Alexander BD, Kontoyiannis DP, Perl TM, Walker R, Patterson TF, Schuster MG, Lyon GM, Wingard JR, Andes DR, Park BJ, Brandt ME, Pappas PG; TRANSNET Investigators.

Med Mycol. 2015 Jun;53(5):440-6. doi: 10.1093/mmy/myv018. Epub 2015 Apr 23.

PMID:
25908651
39.

Efficacy of the investigational echinocandin ASP9726 in a guinea pig model of invasive pulmonary aspergillosis.

Wiederhold NP, Najvar LK, Matsumoto S, Bocanegra RA, Herrera ML, Wickes BL, Kirkpatrick WR, Patterson TF.

Antimicrob Agents Chemother. 2015 May;59(5):2875-81. doi: 10.1128/AAC.04857-14. Epub 2015 Mar 9.

40.

The novel arylamidine T-2307 maintains in vitro and in vivo activity against echinocandin-resistant Candida albicans.

Wiederhold NP, Najvar LK, Fothergill AW, Bocanegra R, Olivo M, McCarthy DI, Kirkpatrick WR, Fukuda Y, Mitsuyama J, Patterson TF.

Antimicrob Agents Chemother. 2015 Feb;59(2):1341-3. doi: 10.1128/AAC.04228-14. Epub 2014 Dec 1.

41.
42.

Diagnosis and treatment of invasive fungal infections in the cancer patient: recent progress and ongoing questions.

Kontoyiannis DP, Patterson TF.

Clin Infect Dis. 2014 Nov 15;59 Suppl 5:S356-9. doi: 10.1093/cid/ciu591. Review.

43.

The investigational agent E1210 is effective in treatment of experimental invasive candidiasis caused by resistant Candida albicans.

Wiederhold NP, Najvar LK, Fothergill AW, McCarthy DI, Bocanegra R, Olivo M, Kirkpatrick WR, Everson MP, Duncanson FP, Patterson TF.

Antimicrob Agents Chemother. 2015 Jan;59(1):690-2. doi: 10.1128/AAC.03944-14. Epub 2014 Oct 20.

44.

Our 2014 approach to breakthrough invasive fungal infections.

Maschmeyer G, Patterson TF.

Mycoses. 2014 Nov;57(11):645-51. doi: 10.1111/myc.12213. Epub 2014 Jun 25. Review.

PMID:
24963554
45.

Endemic fungal infections in solid organ and hematopoietic cell transplant recipients enrolled in the Transplant-Associated Infection Surveillance Network (TRANSNET).

Kauffman CA, Freifeld AG, Andes DR, Baddley JW, Herwaldt L, Walker RC, Alexander BD, Anaissie EJ, Benedict K, Ito JI, Knapp KM, Lyon GM, Marr KA, Morrison VA, Park BJ, Patterson TF, Schuster MG, Chiller TM, Pappas PG.

Transpl Infect Dis. 2014 Apr;16(2):213-24. doi: 10.1111/tid.12186. Epub 2014 Mar 4.

46.

Evaluation of an early step-down strategy from intravenous anidulafungin to oral azole therapy for the treatment of candidemia and other forms of invasive candidiasis: results from an open-label trial.

Vazquez J, Reboli AC, Pappas PG, Patterson TF, Reinhardt J, Chin-Hong P, Tobin E, Kett DH, Biswas P, Swanson R.

BMC Infect Dis. 2014 Feb 21;14:97. doi: 10.1186/1471-2334-14-97.

47.

A reference laboratory experience of clinically achievable voriconazole, posaconazole, and itraconazole concentrations within the bloodstream and cerebral spinal fluid.

Wiederhold NP, Pennick GJ, Dorsey SA, Furmaga W, Lewis JS 2nd, Patterson TF, Sutton DA, Fothergill AW.

Antimicrob Agents Chemother. 2014;58(1):424-31. doi: 10.1128/AAC.01558-13. Epub 2013 Nov 4.

48.

Daptomycin-induced acute eosinophilic pneumonia: analysis of the current data and illustrative case reports.

Phillips J, Cardile AP, Patterson TF, Lewis JS 2nd.

Scand J Infect Dis. 2013 Oct;45(10):804-8. doi: 10.3109/00365548.2013.805427. Epub 2013 Jul 5. Review.

PMID:
23826793
49.

Rapid emergence of echinocandin resistance in Candida glabrata resulting in clinical and microbiologic failure.

Lewis JS 2nd, Wiederhold NP, Wickes BL, Patterson TF, Jorgensen JH.

Antimicrob Agents Chemother. 2013 Sep;57(9):4559-61. doi: 10.1128/AAC.01144-13. Epub 2013 Jul 1.

50.

Real-world experience in the midst of an Exserohilum meningitis outbreak.

Thompson GR, Kontoyiannis DP, Patterson TF.

JAMA. 2013 Jun 19;309(23):2493-5. doi: 10.1001/jama.2013.6294. No abstract available.

PMID:
23780464

Supplemental Content

Loading ...
Support Center